incidence and epidemiology
Mantle cell lymphoma (MCL) is a less frequent subtype of lymphoid malignancies and represents 6%-9% of malignant lymphoma in Western Europe. The annual incidence of this disease has increased during recent decades to 1-2/100 000 recently. MCL is more common in males than in women with a 3 : 1 ratio.
diagnosis and pathology/molecular biology
Diagnosis should be based on a surgical specimen, preferably a lymph node biopsy. Core biopsies should only be carried out in patients without easily accessible lymph nodes (e.g. retroperitoneal bulk), keeping in mind the heterogeneity of MCL. In the rare cases with leukaemic manifestation only, a bone marrow biopsy may be sufficient if additional diagnostic measures are applied [immunohistochemistry, detection of t(11;14)(q13; q32)]. Fine-needle aspirations are inappropriate for a reliable evaluation of additional risk factors (cytology, cell proliferation).
The histological report should give the diagnosis according to the World Health Organization (WHO) classification and Ki-67 as the most established histomorphological risk factor [1] [I, A]. Most tumours have a classic morphology of small-medium sized cells with irregular nuclei. However, the malignant lymphocytes may present with a spectrum of morphological variants, including small round (resembling chronic lymphocytic leukaemia), marginal zone-like, pleomorphic and blastoid cells. As only the minority of these cases are correctly diagnosed based on classical histology only, review by an expert haematopathologist is advised. Specifically, additional immunohistochemistry for detection of the pathognomonic cyclin D1 overexpression is mandatory.
In the rare cyclin D1-negative cases, detection of Sox-11 may help to establish the diagnosis [2] .
Extended gene expression profiling suggests a more favourable clinical course in cases with low cell proliferation; however, this technique is not yet applicable in clinical routine practice. If possible, additional biopsy material should be stored freshly frozen to allow additional molecular (currently still investigational) analyses.
staging and risk assessment
Since treatment may differ depending on the stage of the disease, initial staging should be thorough, particularly in the rare cases with non-bulky stages I and II (Table 1) . Initial workup should include a computed tomography (CT) scan of the neck, thorax, abdomen and pelvis, and a bone marrow aspirate and biopsy (Table 2) . Positron emission tomography-CT (PET-CT) scan is not mandatory, but may be recommended and is especially useful in the rare limited stages I/II, before localised radiotherapy [IV, C]. Gastrointestinal endoscopy is also recommended in these rare cases to detect asymptomatic involvement. Of note, when analysed, the majority of MCL patients will have gastrointestinal involvement.
Central nervous system involvement is rare in asymptomatic patients at diagnosis, but a lumbar puncture may be considered in high-risk cases [at least two of the following risk factors: blastoid variant, elevated lactate dehydrogenase (LDH), impaired performance status] or neurological symptoms [3] .
A full blood count, blood chemistry including LDH and uric acid as well as screening tests for human immunodeficiency virus (HIV) and hepatitis B and C are required. Staging is carried out according to the Ann Arbor classification system (Table 1) , with mention of bulky disease >5 cm when appropriate.
For prognostic purposes, a 'Mantle cell lymphoma International Prognostic Index' (Table 3 ; web-based calculator: www.european-mcl.net/de/clinical_mipi.php) has been estab-
The evaluation of the Ki-67 proliferative antigen is the most applicable method to evaluate cell proliferation, and is considered the most established biological risk factor in MCL. As the reproducibility of quantitative scores among pathologists may vary, a standardised method has been suggested [5] .
indolent subtype of MCL
Most patients with MCL follow an aggressive clinical course. However, a subset of patients may exhibit a more indolent evolution. These cases are commonly characterised by a non-nodal leukaemic presentation with only bone marrow involvement, and splenomegaly [6] . In addition, cases with low Ki-67 (≤10%) tend to have a more indolent course. SOX-11 negativity may also identify cases with more indolent clinical behaviour. However, its role is controversial and additional p53 mutations may cause an aggressive clinical evolution [7] (Figure 1) .
Unfortunately, there are no markers to definitely predict indolent behaviour, but a short watch-and-wait period under close observation seems to be appropriate in suspected indolent cases with low tumour burden [III, B] [9] . treatment first line stage I-II. In the small proportion of patients with limited nonbulky stages I-II, radiotherapy (involved field, 30-36 Gy) has been suggested to achieve long-term remissions [10] . In contrast, in a randomised study, all patients with early-stage MCL relapsed within 1 year [11] . Thus, a shortened conventional chemotherapy induction followed by consolidating radiation (similar to diffuse large-cell lymphoma) may be most appropriate in these cases [IV, B] .
In stage I-II patients with large tumour burden or adverse prognostic features, systemic therapy as indicated for advanced stages would be appropriate in most cases; a radiation consolidation may be considered, depending on tumour location and anticipated side-effects [IV, B]. stage III-IV induction: In all symptomatic patients and asymptomatic cases with high tumour burden, therapy should be initiated at diagnosis [I, A]. The current therapeutic approach is based on clinical risk factors, symptoms and patient characteristics ( Figure 2 ). elderly patients: Based on a median age of 65 years at first diagnosis, the majority of patients do not qualify for doseintensified regimens. Three prospective first-line trials, a salvage trial and a systematic meta-analysis support an improved overall response, progression-free survival (PFS) and overall survival (OS) if rituximab was added to chemotherapy (Table 4) consolidation/maintenance: Rituximab maintenance significantly improves PFS and even OS after R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) (75% versus 58% after 3 years, P < 0.0001) [I, A] [17] .
RIT consolidation also prolongs PFS after chemotherapy, but its benefit seems to be inferior in comparison to rituximab maintenance [II, B] [22] .
younger patients: Although no curative treatment is available for MCL so far, an intensive approach, e.g. by ASCT, has been demonstrated to induce higher response and survival rates in fit patients, independent of the addition of rituximab [I, B] [23, 24] (Table 5 ).
In addition, a randomised trial confirmed that a cytarabinecontaining induction achieves a significantly improved median time to treatment failure (P = 0.038) and a trend for median OS (P = 0.045) [I, B] [25] . In contrast, an induction based on highdose cytarabine alone achieves only insufficient response rates [III, D] [34] . Therefore, a rituximab containing induction of CHOP and high dose Ara-C followed by high dose consolidation and ASCT is recommended.
In a retrospective study comparison of the Nordic, HOVON and MCL younger protocols, total body irradiation (TBI) before ASCT was confirmed to be beneficial only in partial response (PR) patients [II, B] [35] . In contrast, the benefit of RIT has not been demonstrated in inter-study comparisons.
An upfront, dose-intensified approach (R-Hyper-CVAD, rituximab in combination with fractionated cyclophosphamide, vincristine, anthracycline and dexamethasone) with alternating high-dose methotrexate/cytarabine cycles also achieved very high response and survival rates in phase II studies, but its feasibility is hampered by a significant therapy-associated toxicity [II, C] [31] [32] [33] .
The role of rituximab and lenalidomide maintenance after autologous transplantation is currently being investigated by the randomised LyMa [36] and MCL 0208 trials, respectively.
So far, there are no data to support the application of allogeneic transplantation as part of front-line treatment [II, D] [37] .
relapsed disease
A repeated biopsy is strongly recommended to identify prognostically important features of MCL.
Selection of salvage treatment depends on efficacy of prior regimens. In early relapses (<12-24 months), a non-cross-resistant scheme should be preferred (bendamustine or high-dose-Ara-C containing regimens, e.g. R-BAC after CHOP or vice versa) [38] . Rituximab should be added if the previous antibody-containing scheme achieved >6-12 months duration of remission [IV, B] . In cases of early relapses or in refractory cases, newer targeted approaches should be strongly considered (Figure 2) . Currently, temsirolimus is the only compound registered for relapsed MCL in the EU based on a randomised trial [39] . Among the compounds registered in the United States (bortezomib, ibrutinib and lenalidomide), ibrutinib achieves the highest response rates but longer follow-up is warranted [40] [41] [42] (Table 6 ).
Targeted approaches in combination with immunochemotherapy have been suggested but are still investigational.
Rituximab maintenance has a favourable safety profile and prolongs PFS and OS in relapsed disease [I, A] [59] . However, such a second-line maintenance treatment has not been investigated in patients relapsing after front-line maintenance [IV, D] .
RIT consolidation seems to result in extended remission durations [55] , especially in elderly patients with comorbidities not eligible for dose intensification [IV, B] .
High-dose chemotherapy with ASCT may be considered in patients relapsed after conventional first-line therapy. However, clinical practice guidelines Annals of Oncology the benefit seems to be minor in this setting [60] , and there is no role for a second autograft at relapse. In younger patients, allogeneic stem-cell transplantation is potentially curative and has achieved long-term remissions, even in patients following early relapse and with refractory disease. Based on the advanced age of most patients, a dosereduced conditioning is appropriate [IV, B] [61] . Haplo-identical bone marrow transplantation achieves high response rates but is still experimental in MCL.
response evaluation
Radiological tests should be carried out mid-treatment and following the completion of chemotherapy. Patients who achieve less than a PR should be considered for early salvage regimens. Patients achieving a PR may convert to a complete response after post-induction treatment.
PET-CT for response evaluation is optional [62] .
The independent prognostic role of minimal residual disease (MRD) applying patient-specific primers has been confirmed in numerous studies [63, 64] . However, because of limitations of applicability and the need for qualified and standardised laboratories, its use is advised in clinical trials but not recommended in clinical routine except the setting of donor lymphocyte infusion post allograft. In this disease setting, more research is needed to identify molecular markers which could lead to advances in personalised medicine. The selection of optimal treatment is mainly based on clinical and biological risk factors, symptoms and tumour load (Figure 2) . PET-and MRD-based tailored treatments are currently evaluated in studies but are not yet routine clinical practice.
New agents (especially inhibitors of Bruton's tyrosine kinase as well as PI3 kinases and BCL-2) are currently being investigated [42] .
follow-up and long-term implications
The following recommendations are based on consensus rather than on evidence (see Table 7 ):
• History and physical examination, blood counts and routine chemistry every 3 months for 2 years, every 4-6 months for 3 additional years and subsequently once a year [V, D].
• Annual evaluation of thyroid function in patients with irradiation of the neck.
• Optional CT scan (or chest X-ray/ultrasound examinations to reduce radiation exposure) every 3-6 months for 2 years and every 6-12 months up to 5 years. However, there is no strong evidence to support a regular radiological follow-up. PET-CT should not be used for surveillance. These recommendations are driven by the concern to minimise radiation exposure.
• Some studies suggest that pre-emptive treatment may be efficient. However, MRD screening may be carried out but should not guide therapeutic strategies outside clinical studies. note A summary of recommended treatment strategies outside clinical studies is provided in Figure 2 , and a summary of recommendations is provided in Table 8 . Levels of evidence and grades of recommendation have been applied using the system shown in Table 9 . Statements without grading were considered justified standard clinical practice by the experts and the ESMO faculty.
